Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN LACTOBIONATE versus TAO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN LACTOBIONATE versus TAO.
ERYTHROMYCIN LACTOBIONATE vs TAO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin lactobionate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the translocation of peptides. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Troleandomycin (TAO) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
1-4 g/day IV divided every 6 hours; maximum 4 g/day. Infuse over 20-60 minutes.
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours. For severe infections, up to 500 mg every 6 hours IV.
None Documented
None Documented
Terminal elimination half-life: 1.4-2.0 hours in adults with normal renal function. In patients with anuria, half-life may be prolonged up to 4.8-6.0 hours.
Terminal elimination half-life of 12-24 hours in adults; may be prolonged in hepatic impairment (up to 40-60 hours) and in neonates (2-5 days).
Primarily biliary excretion (80-90% as unchanged drug and metabolites); renal excretion accounts for 10-15% of the dose. Fecal elimination is minimal (<5%).
Primarily hepatic metabolism with <10% excreted unchanged in urine; approximately 30% excreted in feces via bile.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic